German company to buy Eli Lilly’s Lafayette plant

Eli Lilly and Co. will sell its manufacturing plant in Lafayette to a German company in its first major move toward reducing its work force by 5,500 employees and cutting its operating expenses by $1 billion.

Indianapolis-based Lilly signed a nine-year contract with the buyer, Evonik Industries AG, to supply Lilly with the active pharmaceutical ingredients the plant makes. Evonik will offer jobs to the nearly 700 full-time employees at the plant.

“The employees are the key to the success of this deal,” said Tom Bates, president of the North American region for Evonik, which is based in Essen, Germany. He said the company would offer comparable salaries and benefits to the employees. Lilly did not disclose financial terms of the sale, but will take an accounting charge of 23 cents per share, or about $264 million, in its third-quarter financial report, which it will release on Oct. 21.

Some of those costs will come from giving severance packages to all the full-time employees dedicated to the Lafayette site. Lilly did not disclose details of those packages.

About two dozen other employees who are not dedicated to the Lafayette site will relocate to Indianapolis. Also, about two dozen contract employees at the plant will not be offered jobs.

The sale is expected to close by the end of the year.

“This announcement [Oct. 14] certainly supports our goals of becoming a leaner and competitive company given the challenges the company faces,” said Lilly CEO John Lechleiter. Lilly announced its job and cost reduction goals on Sept. 14. It aims to achieve those goals by the end of 2011.

The plant near Lafayette, which is called the Tippecanoe Laboratories, makes active pharmaceutical ingredients for Lilly drugs Cialis, Cymbalta, Gemzar, Alimta and Tylan, an animal health product. It was founded in the 1950s to make large batches of antibiotics.

Because today’s drugs come in smaller doses, the plant has been underutilized. Evonik plans to use that excess capacity to serve other drug companies, both large and small, Bates said.•

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.